Company: KROS
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001664710-25-000046
Chunk: 115

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Item 1
Chunk 115
---
540,562,047 $4 $1,149,195 $(420,328)$728,871 COMMON STOCK $0.0001 PAR VALUEADDITIONALPAID-INCAPITALACCUMULATEDDEFICITTOTAL STOCKHOLDERS’  EQUITY SHARESAMOUNTAs of December 31, 202331,841,084 $3 $713,636 $(381,426)$332,213 Issuance of common stock, net of underwriting discounts, commissions, and offering costs of $9,9434,025,000 — 151,057 — 151,057 Exercise of common stock options201,702 — 5,721 — 5,721 Stock-based compensation— — 8,070 — 8,070 Net income (loss)— — — (43,114)(43,114)As of March 31, 202436,067,786 $3 $878,484 $(424,540)$453,947 

See notes to condensed consolidated financial statements.

7

KEROS THERAPEUTICS, INC.

Condensed Consolidated Statements of Cash Flows 

(In thousands) 

(Unaudited)

THREE MONTHS ENDED MARCH 31,20252024CASH FLOWS FROM OPERATING ACTIVITIES:Net income (loss)$148,451 $(43,114)Adjustments to reconcile net income (loss) to net cash used in operating activities:Depreciation expense344 277 Stock-based compensation expense8,863 8,070 Non-cash lease expense584 339 Changes in operating assets and liabilities:Accounts receivable(14,549)(83)Prepaid expenses and other current assets4,543 (4,478)Other assets1,593 — Accounts payable2,019 23 Right-of-use assets and operating lease liabilities(448)(240)Deferred revenue3,308 — Current tax liability10,043 — Accrued expenses and other current liabilities(3,580)(5,354)Net cash provided by (used in) operating activities161,171 (44,560)CASH FLOWS FROM INVESTING ACTIVITIES:Purchase of property and equipment(565)(946)Net cash used in investing activities(565)(946)CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from